Evidence map›Paper›PMID 42439977›Full record

ArticleEJNMMI research2026

Sarcopenia does not affect total liver function measured using technetium-99m mebrofenin hepatobiliary scintigraphy.

Pieter Arntz, Pim Olthof, Fadi Rassam, Roelof Bennink, Robert-Jan Coelen, Thomas van Gulik, Jan Heil, Geert Kazemier, Bart Takkenberg, Joris Erdmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pieter ArntzCancer Center Amsterdam, Amsterdam UMC, Department of Surgery, University of Amsterdam, VUMC, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands. p.j.arntz@amsterdamumc.nl.ORCID http://orcid.org/0000-0001-8429-3864
Pim OlthofCancer Center Amsterdam, Amsterdam UMC, Department of Surgery, University of Amsterdam, VUMC, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands.
Fadi RassamCancer Center Amsterdam, Amsterdam UMC, Department of Surgery, University of Amsterdam, VUMC, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands.
Roelof BenninkCancer Center Amsterdam, Amsterdam UMC, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Robert-Jan CoelenCancer Center Amsterdam, Amsterdam UMC, Department of Surgery, University of Amsterdam, VUMC, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands.
Thomas van GulikCancer Center Amsterdam, Amsterdam UMC, Department of Surgery, University of Amsterdam, VUMC, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands.
Jan HeilDepartment of General, Visceral and Transplant Surgery, University Hospital Frankfurt, Goethe-University Frankfurt, Frankfurt am Main, Germany.
Geert KazemierCancer Center Amsterdam, Amsterdam UMC, Department of Surgery, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Bart TakkenbergLocation Academic Medical Center, Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Joris ErdmannCancer Center Amsterdam, Amsterdam UMC, Department of Surgery, University of Amsterdam, VUMC, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands. j.i.erdmann@amsterdamumc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatobiliary scintigraphy (HBS) using technetium-99m mebrofenin is used to preoperatively estimate risk of adverse outcomes after major liver resections. Sarcopenia has been independently associated with adverse outcomes after surgery. This retrospective cohort study aimed to correlate patient- and disease-related factors, including sarcopenia, with total liver function (TLF) through HBS analysis.

resultsDuring the study period, 346 patients underwent HBS to quantify TLF. The median TLF was 15.0 (12.1-16.7) %/min. Body composition parameters were not correlated to TLF. Older age, a diagnosis of hepatocellular carcinoma, underlying cirrhosis and high serum bilirubin levels were independently correlated with decreased TLF. In contrast, the absence of underlying liver disease and overall good health were independently correlated with higher TLF. Sarcopenia was not correlated with TLF.

conclusionSarcopenia does not impact TLF. Total liver function measured with HBS is negatively correlated with older age, a diagnosis of hepatocellular carcinoma, underlying cirrhosis and serum bilirubin level.

Indexed as

CancerHepatectomyLiver function testsRadionuclide imagingSarcopenia

Identifiers

PMID42439977
PMCPMC13421617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.